On the recordSeptember 18, 2014
Do you believe that we need to further incentivize new drug and diagnostic development if we are to appropriately address the issue of antibiotic resistance, and if so, what would you recommend?
Source
congress.govJoe Pitts: “Do you believe that we need to further incentivize new drug and diagnostic development if we are to appropriately…”
Editor's note · Context
Pitts questions the need for incentives in drug development for antibiotic resistance.
Share
More from Joe Pitts
Sep 13, 2016
I for one in a portion of my life when I was a boy lived in a household where we didn't have access to health care.
Dec 6, 2016
Both the FDA and the General Accountability Office agree that there is no food safety justification for this regulatory divide.
Nov 29, 2016
Today's hearing will be taking a close look at the United States Preventive Services Task Force, created in 1984 as an independent, volunteer panel of 16 national experts in prevention, primary care, and evidence-based medicine and tasked…
Other voices in this conversation
